By Fineline Cube 
US-based science and tech services giant Danaher Corporation (NYSE: DHR) announced a strategic partnership with UK-based major AstraZeneca (AZ, NASDAQ: AZN) this week. The collaboration aims to enhance the ability of clinicians to accurately identify patients who are most likely to benefit from precision medicines, leveraging advanced technologies and solutions.
Leveraging Danaher Centers for Enabling Precision Medicine
The partnership will utilize Danaher’s newly established Danaher Centers for Enabling Precision Medicine to streamline the end-to-end development of precision medicine solutions. The first product under this collaboration will incorporate technology from Danaher’s subsidiary, Leica Biosystems. The initial focus will be on digital pathology and computational pathology solutions, as well as AI-powered diagnostic algorithms, aiming to improve diagnostic accuracy and patient outcomes.
Driving Innovation in Diagnostic Solutions
By combining Danaher’s expertise in scientific and technology services with AstraZeneca’s strengths in pharmaceutical research and development, the partnership is poised to accelerate the adoption of precision medicine. This collaboration underscores the commitment of both companies to drive innovation in diagnostic solutions and enhance the delivery of personalized healthcare.-Fineline Info & Tech